De-Risking FIH: Integrated Strategies for Rapid Proof-of-Concept

Quotient’s Translational Pharmaceutics® approach is proven to accelerate development programs by leveraging a purpose-built infrastructure to develop formulations, provide GMP or compounded drug products to deliver quality clinical data.

In this case, Translational Pharmaceutics® was used to support the FIH study and streamlined the process from SAD initiation to positive PoC in patients in just 18 months.

Learn more about how Quotient Sciences recently helped a customer navigate a new molecular entity for hereditary angioedema (HAE) through early clinical trials. As an orphan indication, patient recruitment for an HAE trial was a known challenge.